|
Avaliação DCF da Nektar Therapeutics (NKTR)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Nektar Therapeutics (NKTR) Bundle
Simplifique sua análise e melhore a precisão com a calculadora DCF NKTR (Nektar Therapeutics)! Equipado com dados reais de Nektar e suposições personalizáveis, essa ferramenta permite que você preveja, avalie e valorize o NKTR como um investidor experiente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.6 | 152.9 | 101.9 | 92.1 | 90.1 | 87.5 | 84.9 | 82.4 | 80.0 | 77.7 |
| Revenue Growth, % | 0 | 33.41 | -33.36 | -9.67 | -2.1 | -2.93 | -2.93 | -2.93 | -2.93 | -2.93 |
| EBITDA | -382.7 | -394.3 | -463.0 | -323.9 | -243.1 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| EBITDA, % | -333.89 | -257.87 | -454.3 | -351.82 | -269.75 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 11.0 | 12.5 | 13.0 | 12.2 | 7.8 | 9.2 | 8.9 | 8.6 | 8.4 | 8.1 |
| Depreciation, % | 9.6 | 8.17 | 12.76 | 13.25 | 8.67 | 10.49 | 10.49 | 10.49 | 10.49 | 10.49 |
| EBIT | -393.7 | -406.8 | -476.0 | -336.1 | -250.9 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| EBIT, % | -343.49 | -266.05 | -467.06 | -365.08 | -278.42 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1,324.9 | 1,061.9 | 734.0 | 505.0 | 303.6 | 87.5 | 84.9 | 82.4 | 80.0 | 77.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 36.8 | 38.9 | 22.5 | 6.0 | 2.3 | 15.5 | 15.0 | 14.6 | 14.2 | 13.8 |
| Account Receivables, % | 32.11 | 25.43 | 22.07 | 6.5 | 2.5 | 17.72 | 17.72 | 17.72 | 17.72 | 17.72 |
| Inventories | 12.7 | 15.3 | 15.8 | 19.2 | 16.1 | 13.2 | 12.8 | 12.4 | 12.0 | 11.7 |
| Inventories, % | 11.05 | 10 | 15.51 | 20.86 | 17.87 | 15.06 | 15.06 | 15.06 | 15.06 | 15.06 |
| Accounts Payable | 19.2 | 22.1 | 9.7 | 13.0 | 9.8 | 11.5 | 11.2 | 10.9 | 10.5 | 10.2 |
| Accounts Payable, % | 16.78 | 14.48 | 9.56 | 14.1 | 10.93 | 13.17 | 13.17 | 13.17 | 13.17 | 13.17 |
| Capital Expenditure | -26.3 | -7.3 | -15.0 | -5.7 | -.9 | -8.7 | -8.4 | -8.2 | -7.9 | -7.7 |
| Capital Expenditure, % | -22.93 | -4.75 | -14.71 | -6.17 | -0.95981 | -9.9 | -9.9 | -9.9 | -9.9 | -9.9 |
| Tax Rate, % | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 |
| EBITAT | -394.2 | -407.3 | -476.5 | -339.0 | -250.7 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -439.8 | -403.8 | -475.0 | -316.2 | -240.1 | -95.6 | -83.9 | -81.5 | -79.1 | -76.8 |
| WACC, % | 12.99 | 12.99 | 12.99 | 12.99 | 12.98 | 12.99 | 12.99 | 12.99 | 12.99 | 12.99 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -297.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -78 | |||||||||
| Terminal Value | -713 | |||||||||
| Present Terminal Value | -387 | |||||||||
| Enterprise Value | -684 | |||||||||
| Net Debt | 82 | |||||||||
| Equity Value | -767 | |||||||||
| Diluted Shares Outstanding, MM | 190 | |||||||||
| Equity Value Per Share | -4.03 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NKTR financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Nektar Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Pre-Loaded Data: Nektar Therapeutics’ historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Edit WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: See Nektar Therapeutics’ intrinsic value recalculate in real time.
- Clear Visual Outputs: Dashboard charts display valuation results and key metrics.
- Built for Accuracy: A professional tool for analysts, investors, and finance experts.
How It Works
- 1. Open the Template: Download and open the Excel file containing Nektar Therapeutics (NKTR) preloaded data.
- 2. Edit Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV for Nektar Therapeutics (NKTR).
- 4. Test Scenarios: Evaluate various forecasts to explore different valuation outcomes for Nektar Therapeutics (NKTR).
- 5. Use with Confidence: Present professional valuation insights to support your investment decisions regarding Nektar Therapeutics (NKTR).
Why Choose This Calculator for Nektar Therapeutics (NKTR)?
- Accurate Data: Up-to-date Nektar Therapeutics financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants focused on Nektar Therapeutics.
- User-Friendly: Easy-to-navigate design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Nektar Therapeutics (NKTR) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Nektar Therapeutics (NKTR).
- Consultants: Deliver professional valuation insights on Nektar Therapeutics (NKTR) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like Nektar Therapeutics (NKTR) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Nektar Therapeutics (NKTR).
What the Template Contains
- Pre-Filled DCF Model: Nektar Therapeutics’ (NKTR) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Nektar Therapeutics’ (NKTR) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.